Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.

Literature DB >> 22461530

Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.

Luigi Buonaguro¹, Maria Tagliamonte, Maria Luisa Visciano, Hanne Andersen, Mark Lewis, Ranajit Pal, Maria Lina Tornesello, Ulf Schroeder, Jorma Hinkula, Britta Wahren, Franco M Buonaguro.

Abstract

Female rhesus macaques were immunized with HIV virus-like particles (HIV-VLPs) or HIV DNA administered as sequential combinations of mucosal (intranasal) and systemic (intramuscular) routes, according to homologous or heterologous prime-boost schedules. The results show that in rhesus macaques only the sequential intranasal and intramuscular administration of HIV-VLPs, and not the intranasal alone, is able to elicit humoral immune response at the systemic as well as the vaginal level.

Entities: Disease Species

Mesh：

Substances：

Year: 2012 PMID： 22461530 PMCID： PMC3370444 DOI： 10.1128/CVI.00068-12

Source DB: PubMed Journal: Clin Vaccine Immunol ISSN： 1556-679X

43 in total

1. A novel glycoprotein 120 sequence from an HIV type 1 isolate of the A clade identified in North Uganda.

Authors: L Buonaguro; F M Buonaguro; F Russo; M L Tornesello; E Beth-Giraldo; R Wagner; H Wolf; G Giraldo
Journal: AIDS Res Hum Retroviruses Date: 1998-09-20 Impact factor: 2.205

2. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals.

Authors: S Mazzoli; D Trabattoni; S Lo Caputo; S Piconi; C Blé; F Meacci; S Ruzzante; A Salvi; F Semplici; R Longhi; M L Fusi; N Tofani; M Biasin; M L Villa; F Mazzotta; M Clerici
Journal: Nat Med Date: 1997-11 Impact factor: 53.440

3. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses.

Authors: C Sedlik; A Dridi; E Deriaud; M F Saron; P Rueda; J Sarraseca; J I Casal; C Leclerc
Journal: J Virol Date: 1999-04 Impact factor: 5.103

4. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men.

Authors: Sergio Lo Caputo; Daria Trabattoni; Francesca Vichi; Stefania Piconi; Lucia Lopalco; Maria Luisa Villa; Francesco Mazzotta; Mario Clerici
Journal: AIDS Date: 2003-03-07 Impact factor: 4.177

5. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV.

Authors: Yoshimi Enose; Masahiro Ui; Ariko Miyake; Hajime Suzuki; Hiromi Uesaka; Takeo Kuwata; Jun Kunisawa; Hiroshi Kiyono; Hidemi Takahashi; Tomoyuki Miura; Masanori Hayami
Journal: Virology Date: 2002-07-05 Impact factor: 3.616

6. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

Authors: Ronald S Veazey; Robin J Shattock; Melissa Pope; J Christian Kirijan; Jennifer Jones; Qinxue Hu; Tom Ketas; Preston A Marx; Per Johan Klasse; Dennis R Burton; John P Moore
Journal: Nat Med Date: 2003-02-10 Impact factor: 53.440

7. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.

Authors: Ariko Miyake; Takami Akagi; Yoshimi Enose; Masamichi Ueno; Masaki Kawamura; Reii Horiuchi; Katsuya Hiraishi; Masakazu Adachi; Takeshi Serizawa; Opendra Narayan; Mitsuru Akashi; Masanori Baba; Masanori Hayami
Journal: J Med Virol Date: 2004-07 Impact factor: 2.327

8. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis.

Authors: M Haile; U Schröder; B Hamasur; A Pawlowski; T Jaxmar; G Källenius; S B Svenson
Journal: Vaccine Date: 2004-03-29 Impact factor: 3.641

9. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

Authors: L Buonaguro; L Racioppi; M L Tornesello; C Arra; M L Visciano; B Biryahwaho; S D K Sempala; G Giraldo; F M Buonaguro
Journal: Antiviral Res Date: 2002-06 Impact factor: 5.970

10. Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program.

Authors: L Buonaguro; E Del Guadio; M Monaco; D Greco; P Corti; E Beth-Giraldo; F M Buonaguro; G Giraldo
Journal: J Virol Date: 1995-12 Impact factor: 5.103

6 in total

1. Self-encapsulating Poly(lactic-co-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery.

Authors: Brittany A Bailey; Kashappa-Goud H Desai; Lukasz J Ochyl; Susan M Ciotti; James J Moon; Steven P Schwendeman
Journal: Mol Pharm Date: 2017-08-22 Impact factor: 4.939

2. Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011.

Authors: Nicolas Ruffin; Marie Borggren; Zelda Euler; Fabio Fiorino; Katrijn Grupping; David Hallengärd; Aneele Javed; Kevin Mendonca; Charlotte Pollard; David Reinhart; Elisa Saba; Enas Sheik-Khalil; Annette Sköld; Serena Ziglio; Gabriella Scarlatti; Frances Gotch; Britta Wahren; Robin J Shattock
Journal: J Transl Med Date: 2012-07-11 Impact factor: 5.531

3. Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate.

Authors: Maria Luisa Visciano; Maria Tagliamonte; Guillaume Stewart-Jones; Leo Heyndrickx; Guido Vanham; Marianne Jansson; Anders Fomsgaard; Berit Grevstad; Meghna Ramaswamy; Franco M Buonaguro; Maria Lina Tornesello; Priscilla Biswas; Gabriella Scarlatti; Luigi Buonaguro
Journal: J Transl Med Date: 2013-07-08 Impact factor: 5.531